Sublingual immunotherapy approved for grass pollen allergies.

The article talks about Oralair, the first sublingual immunotherapy alternative for immunotherapy injections for people 10 to 65 years old who suffer from grass pollen allergies manufactured by French pharmaceutical company Stallergenes, S.A. Oralair was approved by the U.S. Food and Drug Administration and will be marketed in the U.S. in partnership with Greer Laboratories Inc. The drug contains sweet vernal-grass, orchardgrass, ryegrass, timothy or Kentucky bluegrass pollen extracts.